Apr 01, 2020
Stealth BioTherapeutics Reports Fiscal Year 2019 Financial Results And Recent Business Highlights
Mar 30, 2020
Stealth BioTherapeutics to Report Full Year 2019 Financial Results on Wednesday, April 1, 2020
Mar 03, 2020
FDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth Syndrome
Feb 18, 2020
Stealth BioTherapeutics Announces Positive Results From Study to Evaluate Efficacy of Elamipretide in Barth Patients Compared to Natural History Control
Dec 20, 2019
Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy
Nov 19, 2019
Stealth Biotherapeutics to Present at Jefferies 2019 London Healthcare Conference
Nov 14, 2019
Stealth BioTherapeutics Reports Third Quarter 2019 Financial Results And Recent Business Highlights
Nov 11, 2019
Stealth Biotherapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
Oct 17, 2019
Stealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth Syndrome
Oct 07, 2019
Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
Oct 01, 2019
Stealth Biotherapeutics to Present at the 2019 Cantor Global Healthcare Conference
Sep 20, 2019
Stealth BioTherapeutics to Attend Upcoming Investor Conferences
Sep 03, 2019
Stealth BioTherapeutics Announces Appointment of Robert Weiskopf as Chief Financial Officer
Aug 14, 2019
Stealth BioTherapeutics Reports First Half 2019 Financial Results And Recent Business Highlights
Jul 02, 2019
Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders
May 30, 2019
Stealth Biotherapeutics to Present at Upcoming Investor Conferences
May 15, 2019
Stealth BioTherapeutics Reports First Quarter 2019 Financial Results And Recent Business Highlights
Apr 25, 2019
Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy
Apr 16, 2019
Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial
Apr 04, 2019
Stealth BioTherapeutics Reports Fiscal Year 2018 Financial Results and Recent Business Highlights